NCT05548634View on ClinicalTrials.gov

A Study of TAVO412 in Patients with Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 1, 2026

Conditions
Cancer
Interventions
DRUG

TAVO412

Biologic

Trial Locations (1)

10029

Tisch Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Tavotek Biotherapeutics

INDUSTRY

NCT05548634 - A Study of TAVO412 in Patients with Cancer | Biotech Hunter | Biotech Hunter